Design and characterization of metoprolol floating matrix tablet

Vasudha Bakshi, Swapna S., Deepa Kumari Choudhary, Ch. Revanth, B. Sai KumarCh. Praveen, Ch. Praveen

Abstract


Objective: The objective of the present research was to develop a matrix embedded floating tablet of Metoprolol for the sustained activity and prolongation of gastric residence time to improve the bioavailability of the drug. Metoprolol was chosen as a model drug because it is better absorbed in the stomach than the lower gastro intestinal tract.

Methods: The experimental work was divided into pre-formulation studies, formulation development, and evaluation. Standardization of drug and excipients confirmed the authentication of the samples. Floating test were conducted for all formulations, In vitro dissolution studies were carried out in a dissolution testing apparatus-II, FTIR study was performed to interpret the drug ,excipient interaction.

Results: Floating tests were also performed for 15 formulations and among them five formulations have passed the floating tests (F1, F3, F5, F7, and F14). The In-vitro release kinetics study of this tablet indicated sustained release for Metoprolol and followed zero order release and 95% drug in 8 h in vitro. The drug release profile of formulated product was compared with marketed product Metolar. The floating tablets extended the drug release up to 8 hours. The drug-polymer interaction was evaluated by fourier transform infrared spectroscopy (FTIR).

Conclusions: F3 formulation showed the best floating results. The comparative study between F3 and Metolar (Marketed Product) showed the similar in vitro drug release profile. Thus, the optimzed formulation F-3 can be successfully used for the management of hypertension.


Keywords


Matrix Tablet, Lag time, Metoprolol, Metolar

Full Text:

PDF HTML XML

References


Sung SH, Cheng HM, Wang KL, Yu WC, Chuang SY, Ting CT, et al. White coat hypertension is more risky than prehypertension: important role of arterial wave reflections. Hypertension. 2013;61:1346–53.

Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793–801

Banker GS, Rhodes CT. Modern Pharmaceutics, 4th Edition, 121. Marcel Dekker, Inc; 2005: 501-514.

Lee TW, Robinson JR. Controlled Release Drug Delivery system, In the Science and Practice of Pharmacy, Volume 1, 20th edition; 2001: 903.

Chein YW. Oral Drug Delivery System, Novel drug delivery Systems, volume 50, 2nd Edition, Marcel Dekker, Inc; 139-157.

Lundborg P, Abrahamsson B, Wieselgren I, Walter M. Pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers, Eur J Clin Pharmacol. 1993;45(2):161-3.

Park H, Park K. Gastroretentive drug delivery systems. crit. Reviews in Ther. Drug carrier systems. 1998;15(3):243-84.

Lachman L, Lieberman HA. The theory and practice of industrial pharmacy. Special Indian edition; 2009: 293-373.

Wise DL, Hand Book of Pharmaceutical Controlled Release Technology, Marcel Dekker Inc; 2005: 435-440.

Gilbert S. Banker, Christopher T. Rhodes, Modern Pharmaceutics, 4th Edition, Marcel Dekker Inc, 2005: 501-514.

Remington. 20th ed. The Science and Practice of Pharmacy. Lippincott Williams & Wilkins, Delhi; 2002: 903–914.




DOI: http://dx.doi.org/10.26510/2394-0859.pbe.2017.18

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.



Creative Commons License

 

© Copyright 2018 - Pharmaceutical and Biological Evaluations